HC Wainwright Reiterates “Buy” Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $30.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 258.85% from the company’s previous close. Several other […]
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $30.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 258.85% from the company’s previous close. Several other […]
